{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T19:51:08Z","timestamp":1794599468489,"version":"4.9.1"},"reference-count":109,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy remains a major challenge in B-cell acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (B-NHL). One of the main strategies to avoid CD19-negative relapse has been the development of dual CAR T cells targeting CD19 and an additional target, such as CD22 or CD20. Different methods have been used to achieve this, including coadministration of 2 products targeting 1 single antigen, cotransduction of autologous T cells, use of a bicistronic vector, or the development of bivalent CARs. Phase 1 and 2 trials across all manufacturing strategies have shown this to be a safe approach with equivalent remission rates and initial product expansion. CAR T-cell persistence remains a significant issue, with the majority of relapses being antigen-positive after CAR T-cell infusion. Further, despite adding a second antigen, antigen-negative relapses have not yet been eliminated. This review summarizes the state of the art with dual-targeting CAR T cells for B-cell ALL and B-NHL, the challenges encountered, and possible next steps to overcome them.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013586","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T21:45:53Z","timestamp":1733348753000},"page":"704-721","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1558-1701","authenticated-orcid":false,"given":"Gustavo","family":"de Oliveira Canedo","sequence":"first","affiliation":[{"name":"1Molecular and Cellular Immunology Section, University College London Great Ormond Street Institute of Child Health, London, United Kingdom"},{"name":"2Department of Bone Marrow Transplant, Great Ormond Street Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4901-5858","authenticated-orcid":false,"given":"Claire","family":"Roddie","sequence":"additional","affiliation":[{"name":"3Department of Haematology, University College London Hospitals, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0480-3911","authenticated-orcid":false,"given":"Persis J.","family":"Amrolia","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Immunology Section, University College London Great Ormond Street Institute of Child Health, London, United Kingdom"},{"name":"2Department of Bone Marrow Transplant, Great Ormond Street Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"16","key":"2025032418220842200_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9967","key":"2025032418220842200_bib2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"2025032418220842200_bib3","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025032418220842200_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2025032418220842200_bib5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"issue":"9","key":"2025032418220842200_bib6","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2025032418220842200_bib7","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025032418220842200_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10299","key":"2025032418220842200_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2025032418220842200_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"17","key":"2025032418220842200_bib11","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025032418220842200_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-024-01038-2","article-title":"Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r\/r ALL through a national access scheme","volume":"14","author":"Oporto Espuelas","year":"2024","journal-title":"Blood Cancer J"},{"issue":"26","key":"2025032418220842200_bib13","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025032418220842200_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2025032418220842200_bib15","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032418220842200_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"2025032418220842200_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10254","key":"2025032418220842200_bib18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"17","key":"2025032418220842200_bib19","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2025032418220842200_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"key":"2025032418220842200_bib21","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"2025032418220842200_bib22","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.2020009432","article-title":"CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR\u2013refractory large B-cell lymphoma","volume":"137","author":"Baird","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2025032418220842200_bib23","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"32","key":"2025032418220842200_bib24","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2025032418220842200_bib25","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/bloodadvances.2024012928","article-title":"Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas","volume":"8","author":"Bender","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2025032418220842200_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2025032418220842200_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025032418220842200_bib28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2025032418220842200_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-020-00197-1","article-title":"Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies","volume":"8","author":"Nie","year":"2020","journal-title":"Biomark Res"},{"key":"2025032418220842200_bib30","doi-asserted-by":"crossref","first-page":"102268","DOI":"10.1016\/j.eclinm.2023.102268","article-title":"Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns","volume":"65","author":"Barsan","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"6","key":"2025032418220842200_bib31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat Cancer"},{"issue":"6","key":"2025032418220842200_bib32","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"2025032418220842200_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"9","key":"2025032418220842200_bib34","doi-asserted-by":"crossref","first-page":"110079","DOI":"10.1016\/j.celrep.2021.110079","article-title":"CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia","volume":"37","author":"Zebley","year":"2021","journal-title":"Cell Rep"},{"issue":"6","key":"2025032418220842200_bib35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2025032418220842200_bib36","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"2025032418220842200_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V71.1.13.13","article-title":"Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins","volume":"71","author":"Uckun","year":"1988","journal-title":"Blood"},{"issue":"11","key":"2025032418220842200_bib38","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"2025032418220842200_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/cyto.b.20030","article-title":"Diminished expression of CD19 in B-cell lymphomas","volume":"63","author":"Yang","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"2025032418220842200_bib40","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"2025032418220842200_bib41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/ITT.S288546","article-title":"Targeting CD22 for the treatment of B-cell malignancies","volume":"10","author":"Shah","year":"2021","journal-title":"ImmunoTargets Ther"},{"issue":"12","key":"2025032418220842200_bib42","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2025032418220842200_bib43","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results","volume":"38","author":"Schultz","year":"2024","journal-title":"Leukemia"},{"key":"2025032418220842200_bib44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/B978-0-7216-0081-9.50019-4","volume-title":"The Lymphomas","author":"Zelenetz","year":"2006","edition":"2nd ed"},{"issue":"3","key":"2025032418220842200_bib45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.2008.001024","article-title":"CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure","volume":"94","author":"Johnson","year":"2009","journal-title":"Haematologica"},{"issue":"5","key":"2025032418220842200_bib46","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjh.19348","article-title":"The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies","volume":"204","author":"Brillembourg","year":"2024","journal-title":"Br J Haematol"},{"issue":"13","key":"2025032418220842200_bib47","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.3390\/cancers14133230","article-title":"Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers"},{"issue":"586","key":"2025032418220842200_bib48","doi-asserted-by":"crossref","first-page":"eabc6401","DOI":"10.1126\/scitranslmed.abc6401","article-title":"Trispecific CD19-CD20-CD22\u2013targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models","volume":"13","author":"Schneider","year":"2021","journal-title":"Sci Transl Med"},{"issue":"10","key":"2025032418220842200_bib49","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"2025032418220842200_bib50","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial","volume":"41","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2025032418220842200_bib51","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med"},{"issue":"11","key":"2025032418220842200_bib52","doi-asserted-by":"crossref","first-page":"910.e1","DOI":"10.1016\/j.jtct.2021.08.012","article-title":"CD19\/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed\/refractory aggressive B cell lymphomas","volume":"27","author":"Cao","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2025032418220842200_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025032418220842200_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-022-00270-5","article-title":"A\u00a0novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed\/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"2025032418220842200_bib55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2025032418220842200_bib56","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"issue":"11","key":"2025032418220842200_bib57","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","article-title":"Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study","volume":"24","author":"Pan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2025032418220842200_bib58","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2018-99-113126","article-title":"Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032418220842200_bib59","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2021-148881","article-title":"SCRI-CAR19x22v2\u00a0T cell product demonstrates bispecific activity in B-ALL","volume":"138","author":"Annesley","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2025032418220842200_bib60","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025032418220842200_bib61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"8","key":"2025032418220842200_bib62","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"2025032418220842200_bib63","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2025032418220842200_bib64","doi-asserted-by":"crossref","first-page":"E338","DOI":"10.1002\/ajh.27076","article-title":"Long-term follow-up of tandem CD19\/CD22 CAR T-Cells in r\/r B-ALL patients with high-risk features","volume":"98","author":"Cui","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2025032418220842200_bib65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-023-00813-x","article-title":"CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study","volume":"13","author":"Niu","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025032418220842200_bib66","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025032418220842200_bib67","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.ymthe.2023.03.020","article-title":"Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR","volume":"31","author":"Kokalaki","year":"2023","journal-title":"Mol Ther"},{"key":"2025032418220842200_bib68","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0","year":"2017"},{"issue":"4","key":"2025032418220842200_bib69","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2025032418220842200_bib70","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"21","key":"2025032418220842200_bib71","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2025032418220842200_bib72","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2025032418220842200_bib73","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov"},{"issue":"10","key":"2025032418220842200_bib74","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"2025032418220842200_bib75","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ajh.26718","article-title":"Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells","volume":"97","author":"Zurko","year":"2022","journal-title":"Am J Hematol"},{"issue":"14","key":"2025032418220842200_bib76","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025032418220842200_bib77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"2025032418220842200_bib78","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","article-title":"Sequential CD19\/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma","volume":"11","author":"Wu","year":"2021","journal-title":"Blood Cancer J"},{"issue":"20","key":"2025032418220842200_bib79","first-page":"2470","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025032418220842200_bib80","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","article-title":"CD19\/CD22 dual-targeted CAR T-cell therapy for relapsed\/refractory aggressive B-cell lymphoma: a safety and efficacy study","volume":"9","author":"Wei","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"2025032418220842200_bib81","doi-asserted-by":"crossref","first-page":"664421","DOI":"10.3389\/fonc.2021.664421","article-title":"A\u00a0prospective investigation of bispecific CD19\/22 CAR T cell therapy in patients with relapsed or refractory B cell non-Hodgkin lymphoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"2025032418220842200_bib82","doi-asserted-by":"crossref","first-page":"e3227","DOI":"10.1002\/hon.3227","article-title":"Tislelizumab augment the efficacy of CD19\/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"42","author":"Zhang","year":"2024","journal-title":"Hematol Oncol"},{"issue":"9","key":"2025032418220842200_bib83","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A\u00a0novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov"},{"issue":"6","key":"2025032418220842200_bib84","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T\u00a0cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"2025032418220842200_bib85","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"issue":"16 suppl","key":"2025032418220842200_bib86","doi-asserted-by":"crossref","first-page":"CT055","DOI":"10.1158\/1538-7445.AM2020-CT055","article-title":"Abstract CT055: phase 1\/2 primary analysis of ZUMA-6: axicabtagene ciloleucel (axi-cel) in combination with atezolizumab (atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)","volume":"80","author":"Jacobson","year":"2020","journal-title":"Cancer Res"},{"issue":"27","key":"2025032418220842200_bib87","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025032418220842200_bib88","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025032418220842200_bib89","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2025032418220842200_bib90","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/cancers10060200","article-title":"Overcoming resistance of human non-Hodgkin\u2019s lymphoma to CD19-CAR CTL therapy by celecoxib and histone deacetylase inhibitors","volume":"10","author":"Torres-Collado","year":"2018","journal-title":"Cancers"},{"issue":"1","key":"2025032418220842200_bib91","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"issue":"35","key":"2025032418220842200_bib92","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2025032418220842200_bib93","doi-asserted-by":"crossref","first-page":"e150807","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2025032418220842200_bib94","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat Med"},{"issue":"9","key":"2025032418220842200_bib95","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing ex\u00a0vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"2025032418220842200_bib96","doi-asserted-by":"crossref","first-page":"e95103","DOI":"10.1172\/jci.insight.95103","article-title":"Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy","volume":"2","author":"Klebanoff","year":"2017","journal-title":"JCI Insight"},{"issue":"9","key":"2025032418220842200_bib97","doi-asserted-by":"crossref","first-page":"e007002","DOI":"10.1136\/jitc-2023-007002","article-title":"AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival","volume":"11","author":"Mehra","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"2025032418220842200_bib98","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12967-016-0973-y","article-title":"A\u00a0short CD3\/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy","volume":"14","author":"Alvarez-Fern\u00e1ndez","year":"2016","journal-title":"J\u00a0Transl Med"},{"issue":"6434","key":"2025032418220842200_bib99","doi-asserted-by":"crossref","first-page":"eaau0135","DOI":"10.1126\/science.aau0135","article-title":"T\u00a0cell stemness and dysfunction in tumors are triggered by a common mechanism","volume":"363","author":"Vodnala","year":"2019","journal-title":"Science"},{"issue":"18","key":"2025032418220842200_bib100","doi-asserted-by":"crossref","first-page":"e122299","DOI":"10.1172\/jci.insight.122299","article-title":"Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity","volume":"3","author":"Pilipow","year":"2018","journal-title":"JCI Insight"},{"issue":"620","key":"2025032418220842200_bib101","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci Transl Med"},{"issue":"14","key":"2025032418220842200_bib102","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood.2021012714","article-title":"Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy","volume":"139","author":"Yoshikawa","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2025032418220842200_bib103","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/bloodadvances.2024012885","article-title":"Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia","volume":"8","author":"Myers","year":"2024","journal-title":"Blood Adv"},{"issue":"27","key":"2025032418220842200_bib104","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2025032418220842200_bib105","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2025032418220842200_bib106","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2025032418220842200_bib107","doi-asserted-by":"crossref","first-page":"e003644","DOI":"10.1136\/jitc-2021-003644","article-title":"Factors associated with the clinical outcome of patients with relapsed\/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy","volume":"9","author":"Ortiz-Maldonado","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"15","key":"2025032418220842200_bib108","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2025032418220842200_bib109","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/bloodadvances.2023011168","article-title":"Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy","volume":"8","author":"Gabelli","year":"2024","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/704\/2355638\/blooda_adv-2024-013586-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/704\/2355638\/blooda_adv-2024-013586-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T19:59:40Z","timestamp":1742846380000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/704\/534321\/Dual-targeting-CAR-T-cells-for-B-cell-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013586","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}